阿立哌唑一月注射一次制剂治疗伴有和不伴有共病物质使用的精神分裂症的症状和整体功能有效 - ReLiAM 研究的事后分析。
Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the ReLiAM study.
机构信息
Schizophrenia Program, McGill University Health Centre, Montreal, QC, Canada.
Department of Psychiatry, McGill University, Montreal, QC, Canada.
出版信息
BMC Psychiatry. 2022 Dec 8;22(1):773. doi: 10.1186/s12888-022-04397-x.
BACKGROUND
ReLiAM, Real-Life Assessment of Abilify Maintena, was the first reported long-term prospective non-interventional study for patients with schizophrenia treated with aripiprazole once-monthly injectable formulation (AOM) under real-life conditions. ReLiAM's primary aim was to evaluate the evolution of global functional status in patients treated with AOM for 12 months in Canada.
METHODS
The objective of this post hoc analysis of the ReLiAM study is to investigate the treatment effects of real-life use of AOM over a 1-year period in the subgroup of patients with reported substance use compared with patients without substance use.
RESULTS
The results of this post hoc analysis demonstrate that treatment with AOM for 12 months in patients with schizophrenia was comparably effective in improving global functioning in subgroups of patients with and without concomitant substance use.
CONCLUSIONS
These results support the use of AOM for the treatment of schizophrenia in patients with or without concomitant substance use.
TRIAL REGISTRATION
ClinicalTrials.gov NCT02131415, first posted on May 6, 2014. Overall trial status: Terminated.
背景
ReLiAM 是首个报告的在真实环境下，针对接受阿立哌唑每月注射一次制剂（AOM）治疗的精神分裂症患者进行的长期前瞻性非干预性研究。ReLiAM 的主要目的是评估在加拿大接受 AOM 治疗 12 个月的患者的整体功能状态的演变。
方法
本项 ReLiAM 研究的事后分析旨在调查在 1 年期间，与无物质使用的患者相比，报告有物质使用的患者接受 AOM 实际应用的治疗效果。
结果
这项事后分析的结果表明，在伴有或不伴有合并物质使用的精神分裂症患者中，使用 AOM 治疗 12 个月可相当有效地改善整体功能。
结论
这些结果支持在伴有或不伴有合并物质使用的精神分裂症患者中使用 AOM 治疗。
试验注册
ClinicalTrials.gov NCT02131415，首次于 2014 年 5 月 6 日发布。总体试验状态：已终止。
Zotero 插件